1. Scrip
  2. >>Business

Japan’s AGC Makes Agreed €240m Bid For MolMed

Silvio Berlusconi’s Fininvest holds 23% in the cancer-focused biotech

 
• By Sten Stovall

AGC of Japan is offering to buy cell and gene therapy specialist MolMed SPA in a deal worth up to €240m and backed by the biotech’s biggest shareholder, Silvio Berlusconi’s Fininvest.

M&A
AGC wants to catch clinical-stage Italian biotech MolMed • Source: Shutterstock

AGC Inc. of Japan, part of the Mitsubishi conglomerate, has launched a takeover bid for all of Milan-based MolMed SPA in a deal valued at €240m and which is being backed by the biotech’s biggest shareholder, former Italian Prime Minister Silvio Berlusconi’s investment vehicle Fininvest.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.

Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down

 
• By Mandy Jackson

Restructuring Edition: ESSA and Elevation are reviewing strategic alternatives after trial failures, but each has an investor urging them to liquidate. Also, Third Harmonic and Vincerx are winding down, while Keros and Tempest are assessing options, but Opthea and OPM are cutting jobs.